Concomitant use of strong CYP3A inhibitors during initiation and ramp-up phase is contra-indicated.
- TRADE NAME: Venclexta (AbbVie)
- INDICATIONS: Chronic lymphocytic leukemia in patients with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy
- CLASS: BCL-2 inhibitor
- HALF-LIFE: 26 hours
- FDA APPROVAL DATE: 04/11/2016
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Azithromycin, Bosentan, Captopril, Carbamazepine, Carvedilol, Ciprofloxacin, Clarithromycin, Conivaptan, Cyclosporine, Digoxin, Diltiazem, Dronedarone, Efavirenz, Erythromycin, Etravirine, Everolimus, Felodipine, Fluconazole, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Live vaccines, Lopinavir, Modafinil, Nafcillin, Phenytoin, Posaconazole, Quercetin, Quinidine, Ranolazine, Rifampin, Ritonavir, Sirolimus, St John's Wort, Stong or moderate P-gp inhibitors or substrates, Strong or moderate CYP3A inducers or inhibitors, Telaprevir, Ticagrelor, Verapamil, Voriconazole - PREGNANCY: May cause fetal harm
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
